7 Best Peptides for Eye Health

What to Know Before Choosing a Peptide for Eye Health

The peptide landscape for eye health sits in an unusual position. Some of these compounds are being studied in rigorous human trials at major research institutions, while others circulate almost entirely through biohacking communities with little or no clinical data behind them. A useful guide covers both, and that is what this one does.

A compound earns a place on this list because people are using it or actively discussing using it for eye health. That includes research-stage compounds in active trials, compounds used off-label under physician supervision, and research-only peptides whose evidence comes primarily from community protocols. Evidence strength is stated honestly for each entry rather than used as a filter, because a compound people are genuinely reaching for deserves to be named and described accurately, even when its evidence is thin.

One framing point worth stating before the entries begin: no peptide is currently FDA-approved specifically for general eye health or vision maintenance. The landscape divides into compounds with real human trial data for specific eye conditions, compounds with strong preclinical data in animal models and laboratory tissue, and compounds whose use is driven primarily by biohacking communities reporting their own experiences. All three categories appear here, and each entry identifies which category it belongs to.

The entries are numbered and ordered by how prominently each compound appears in published research and real-world use for eye health. Those numbers are a spine for the list, not a verdict. The right compound for any individual depends on their specific condition, their access to medical supervision, and the guidance of a qualified practitioner. This article maps the field. It does not choose for you.

1. Elamipretide (SS-31): For Age-Related Visual Decline

Elamipretide, also identified by its research designation SS-31, is a mitochondria-targeting tetrapeptide and the most clinically advanced peptide in this space as of 2026. Its mechanism centers on a phospholipid called cardiolipin, found almost exclusively in the inner membranes of mitochondria, the structures responsible for generating energy inside cells. Elamipretide binds to cardiolipin and, through a combination of electrostatic and physical interactions with the membrane, enhances the formation of what researchers call respiratory supercomplexes, the molecular machinery that keeps energy production running efficiently. The result is improved electron transfer and ATP synthesis. This matters for the eye because photoreceptor cells and retinal ganglion cells are among the most metabolically demanding cells in the human body, and when mitochondrial function declines with age, those cells are among the first to suffer.

In terms of human trial data, elamipretide stands apart from every other compound on this list. A Phase I clinical trial found statistically significant improvements in two measures of visual function. Best-corrected visual acuity improved by an average of 3.6 letters on the standard chart, and low-luminance visual acuity, a measure of how well someone sees in dim light and one of the earliest things to decline in macular degeneration, improved by 5.6 letters. A subsequent Phase II trial missed its primary endpoints, but researchers observed structural benefits and concluded that further trials, particularly in earlier-stage disease, were warranted. A Phase I/II trial investigating elamipretide for AMD, diabetic retinopathy, and related retinal conditions is currently active as of mid-2026.

In the biohacking community, at least one widely circulated account describes a user who began taking elamipretide for mitochondrial health reasons unrelated to vision and then found they no longer needed reading glasses. That is a single anecdotal report and carries all the usual limitations of self-reported outcomes, but it has helped bring the compound to the attention of people who track visual function as part of longevity protocols.

Elamipretide is not commercially available as a consumer product. It has been administered via injection in clinical settings, and some preclinical work has explored eye drop formulations. Access outside of clinical trials sits firmly in the research channel.

2. Thymosin Beta-4 (RGN-259): For Corneal Healing and Dry Eye

Thymosin beta-4 is a naturally occurring 43-amino-acid peptide with a well-established role in tissue repair, cell migration, and inflammation regulation. Its eye health application draws on those same properties at the surface of the eye, specifically the cornea. Formulated as eye drops under the name RGN-259, thymosin beta-4 has been studied as a treatment for dry eye disease and corneal injuries, including a serious condition called neurotrophic keratopathy where corneal nerve damage leaves the eye surface unable to heal normally.

Of all the compounds people discuss for eye health, thymosin beta-4 has the most mature clinical record for corneal applications. Phase II trials for dry eye disease have been completed, making this one of the few compounds in this space with published human trial data for an eye-specific condition. The mechanism is straightforward in principle: the peptide helps corneal cells migrate toward damaged areas, reduces local inflammation, and promotes the tissue remodeling that the cornea needs to repair itself. Because it is formulated as an eye drop rather than an injectable, it also carries a more accessible administration profile for many people.

Thymosin beta-4 is discussed in functional and regenerative medicine circles for surgical recovery, corneal injury, and persistent dry eye that has not responded well to conventional treatments. It is used off-label under physician supervision in some settings. The compound is not FDA-approved for these indications, but the Phase II data places it considerably ahead of most other peptides in this category in terms of formal clinical evidence.

3. PEDF-Derived Peptides (17-mer and H105A): For Photoreceptor Protection

Pigment Epithelium-Derived Factor, commonly abbreviated as PEDF, is a protein produced naturally in the eye that supports photoreceptor cell survival. Researchers have identified short peptide sequences derived from PEDF, specifically a segment called the 17-mer and a variant called H105A, that carry the neuroprotective effects of the full protein in a much smaller, more deliverable form. These peptides are designed to be administered as eye drops, and studies in laboratory models have shown they can reach the retina from the surface of the eye within approximately one hour.

The mechanism involves a receptor on retinal cells called PEDF-R. When PEDF-derived peptides bind to it, they activate a phospholipase signaling process essential for keeping photoreceptors alive. In degenerative conditions like retinitis pigmentosa, photoreceptors face sustained pressure from calcium overload and molecular signals that push cells toward programmed death. The PEDF peptides appear to address both sides of that equation: they reduce calcium buildup, lower levels of a pro-death protein called BAX, and raise levels of a pro-survival protein called BCL2. The H105A variant additionally protects photoreceptors from oxidative stress, the kind of cellular damage linked to cigarette smoke exposure and other environmental factors implicated in retinal degeneration.

The evidence here is not yet from human clinical trials. The strongest findings come from mouse models and from human retinal organoids, lab-grown tissue that closely resembles the human retina. In NIH-funded work published in 2025, H105A kept significantly more photoreceptor cells alive when organoid tissue was exposed to oxidative stress. That is a meaningful step beyond purely animal data, but it is not a human trial. Clinical trials are planned but had not started as of mid-2026. These peptides are best understood as promising candidates at the leading edge of research, not yet accessible outside of laboratory or trial settings.

4. BPC-157: For Corneal Repair and Ocular Tissue Recovery

BPC-157 is a pentadecapeptide, fifteen amino acids long, derived from a partial sequence of a protein found in gastric juice. It has the broadest preclinical evidence base of any off-label peptide people currently use for eye health, with animal studies covering corneal damage, retinal injury, eye fatigue, inflammation, and the structural layer of the cornea called the stroma. Its primary mechanisms relevant to the eye are support of connective tissue restoration, enhancement of microcirculation through encouraging new blood vessel growth, and general tissue regeneration effects.

No human clinical trial data has been published for BPC-157 in any ocular application as of 2026. The evidence driving its use in the biohacking community is animal data and user-reported experience. That said, the animal evidence across multiple eye-related applications is more extensive than for most other off-label compounds in this category, which helps explain why it is one of the most frequently discussed peptides among people pursuing eye health without a formal clinical pathway. Community use typically involves subcutaneous injection for systemic effects, with oral use possible given the compound's unusual stability in stomach acid, though oral administration is considered less targeted for specific eye repair.

The safety picture for BPC-157 in the context of eye health contains real opposing signals worth stating plainly. A mechanism that promotes new blood vessel growth is beneficial in most tissue repair settings but can be problematic in the eye, where abnormal vessel growth is a driver of conditions like wet AMD. Community reports also run in opposite directions: some users describe floaters disappearing or visual clarity improving, while others have reported blurred vision, migraines, and elevated blood pressure following oral use. Those are uncontrolled anecdotal accounts, but the contradictory directions of reported effects suggest the compound behaves differently depending on the individual or the route of administration. Anyone considering BPC-157 for eye health should be aware of these conflicting signals, not just the positive reports.

5. Epithalon: For Retinal Aging and Cell Longevity

Epithalon is a synthetic tetrapeptide that mimics a naturally occurring compound called epithalamin, produced in the pineal gland. It has attracted attention in the biohacking and longevity communities primarily for its proposed effects on cellular aging, specifically its influence on the mechanisms that regulate how long cells continue to divide and function before declining. The eye health interest comes from its proposed capacity to protect retinal cells from age-related degeneration, and it is used in community protocols for conditions including macular issues and macular pucker, a condition where tissue on the macula's surface contracts and distorts vision.

The evidence for epithalon in eye health is at the preclinical and proprietary research stage. Anti-aging and retinal regeneration claims are based on manufacturer data and limited research rather than independent peer-reviewed human trials. No published clinical trial data establishes epithalon's effects on retinal function in human subjects as of 2026. What exists is user-reported experience from community protocols and basic research into its cell lifespan effects.

Within the biohacking community, epithalon is one of the more widely used peptides for eye health, which is why it belongs on this list despite the limited clinical picture. Community use is typically via subcutaneous injection for systemic effects. The compound is a research-only chemical in most markets, obtained through research chemical channels rather than clinical or telehealth pathways.

6. GHK-Cu: For Collagen Support and Accommodation Decline

GHK-Cu is a tripeptide copper complex made up of three amino acids, glycine, histidine, and lysine, bound to a copper ion. Best known in skin and hair health research, it is one of the most studied compounds for collagen stimulation and tissue regeneration. Its relevance to eye health comes from those same collagen-related mechanisms applied to the structural tissues of the eye. The sclera, cornea, trabecular meshwork, extraocular muscles, and lens capsule all rely on collagen for their mechanical properties, and the quality of those structures affects everything from focus sharpness to intraocular pressure regulation.

The specific use case driving community interest in GHK-Cu for eye health is the age-related decline in accommodation, the eye's ability to shift focus between near and distant objects. Accommodation is controlled by the ciliary muscle working in concert with the lens, and as collagen in the lens and surrounding structures stiffens over decades, this capacity diminishes. GHK-Cu is used by some practitioners and biohackers on the premise that its collagen-stimulating effects might support the flexibility of those structures. Improvements in retinal microcirculation are also cited, given the compound's well-characterized effects on blood vessel biology in other contexts.

The evidence is largely animal model and mechanism-based. No independent peer-reviewed human trials have been published on GHK-Cu for ocular applications as of 2026. Its collagen synthesis pathway is well-characterized from skin and wound healing research, which provides a reasonable mechanistic basis for the eye health hypothesis, but that hypothesis has not been directly tested in clinical work. For eye health specifically, subcutaneous injection is considered necessary rather than topical application; the copper peptide products common in skin care are not expected to reach intraocular structures.

7. AXT107: For Abnormal Vessel Leakage in Diabetic Retinopathy

AXT107 is an investigational peptide developed primarily by researchers at Johns Hopkins and is one of the more mechanistically specific compounds in this space. Its design targets the Tie2 protein pathway, which normally maintains the structural integrity of the blood vessels that supply the retina. In conditions like diabetic retinopathy and wet AMD, the proteins that form tight connections between blood vessel cells disperse, and the blood-retinal barrier breaks down. Fluid leaks from the vessels into surrounding retinal tissue, distorting and eventually destroying vision. AXT107 causes Tie2 proteins to migrate back toward cell junctions and congregate there, rebuilding those watertight connections in a mechanism researchers describe as a molecular zipper.

Animal model data shows AXT107 suppresses abnormal blood vessel growth more effectively than aflibercept, one of the standard anti-VEGF treatments for wet AMD, and when the two are combined the suppression is significantly greater than either achieves alone. That synergy with an existing approved treatment is one reason the compound has attracted sustained research attention.

No published human trial results for AXT107 in any eye condition are available as of 2026. Phase 1 and Phase 2 clinical trials were referenced in Johns Hopkins research releases, but human data from ophthalmic applications is not yet in the published literature. AXT107 is a compound to follow as the research pipeline advances rather than one people are currently using off-label in meaningful numbers. It earns a place here because it represents one of the most mechanistically concrete approaches to diabetic retinopathy, a condition affecting tens of millions of people worldwide with limited treatment options.

How These Peptides Compare

Frequently Asked Questions

Are Any Peptides for Eye Health FDA-Approved?

No peptide is currently FDA-approved specifically for general eye health or vision improvement as of 2026. Some compounds in this space, including elamipretide and thymosin beta-4, have completed Phase I or Phase II human clinical trials for specific conditions such as AMD and dry eye, but FDA approval requires completing the full regulatory process, and none of these compounds have done so for ophthalmic indications. The off-label compounds people are currently using for eye health are obtained through research chemical channels or, in some cases, through physician-supervised protocols.

How Are These Peptides Typically Administered?

The route depends on which compound and what application. The biohacking peptides most commonly discussed for eye health, including Epithalon, BPC-157, and GHK-Cu, are typically used via subcutaneous injection when the goal is systemic effects that reach the eye. Newer research-stage peptides like the PEDF-derived compounds and thymosin beta-4 are formulated specifically as eye drops and represent a non-injectable approach. For the compounds currently in clinical trials, administration is conducted under strict medical supervision in trial settings, not self-administered. Understanding which route is appropriate for a given compound is essential before considering any of these options.

What Is the Difference Between Peptide Eye Creams and the Compounds in This Guide?

Peptide eye creams sold in skin care target puffiness, fine lines, and dark circles at the skin surface around the eye area, not inside the eye itself. The compounds covered in this guide target internal eye structures including the cornea, the retina, photoreceptor cells, and the retinal blood vessels. The two categories share the word peptide but have essentially nothing else in common in terms of mechanism, application, or evidence base. If you are researching options for vision function, retinal health, or a diagnosed eye condition, cosmetic peptide products are outside the scope of what this article addresses.

Is BPC-157 Safe to Use Specifically for Eye Health?

The safety picture for BPC-157 in the context of eye health is uncertain and contains genuinely opposing signals. Some community members report improvements in floaters and visual clarity. At the same time, BPC-157 promotes angiogenesis, the growth of new blood vessels, which is a mechanism that can worsen certain eye conditions like wet AMD where abnormal vessel growth is the central problem. Community reports also include cases of blurred vision, migraines, and elevated blood pressure following oral use. No human clinical trial has evaluated BPC-157 for any eye condition, so there is no controlled safety data for this application. Anyone considering it should discuss the angiogenic risk with an eye care professional familiar with their specific diagnosis and history.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for eye health in one place.